25 Aug 23

Cambridge, UK: We are excited to announce that o2h discovery is the finalist for the Most Impactful CRO award at the OBN Awards 2023.

The ‘Most Impactful CRO’ category acknowledges organisations that have demonstrated remarkable achievements in the field of drug discovery services. Our inclusion as a finalist highlights our dedication to providing outstanding drug discovery research services that drive innovation and progress within the biotech industry.

o2h-discovery_OBN-Award-2023

The evaluation process for this esteemed category took into consideration various aspects, including:

  • Business Performance: Assessing our consistent growth and impact of our services on the Biotech and Pharmaceutical market.
  • Strategic R&D Impact: Recognizing our contributions to advancing research and development.
  • Capabilities: Highlighting the distinctive attributes that set us apart.
  • Customer Feedback: Gauging the satisfaction of our valued collaborators.
  • ESG Priorities: Our incorporation of Environmental, Social, and Governance priorities to drive positive change.
  • Management Team: Recognizing the expertise and leadership of our management team.
  • Overall Impact: Evaluating the broader influence of our efforts on the industry.

The OBN Awards ceremony will take place on November 22, 2023 at London, UK, where winners from various categories will be announced. The event promises to bring together industry leaders, innovators, and influencers to celebrate achievements and milestones within the life sciences sector.

 

About o2h discovery:

Founded in 2005, o2h discovery is a Contract Research Organisation which has an integrated drug discovery platform operating from its state-of-the-art research centre in Ahmedabad, India and Cambridge, UK. We have the in-house capability to execute hit-lead-optimization programs leading into patent and IND filing from our state-of-the-art biotechnology incubator with expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of pre-clinical development. 

For more information about o2h discovery, visit: https://www.o2h.com or email discovery@o2h.com.

Press Release – Curza and o2h discovery announce a multi-FTE chemistry collaboration against gram negative